3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
11
Sarcoma
6
Neoplasms
6
Lymphoma, Mantle-Cell
6
Prostatic Neoplasms
5
Lymphoma, Non-Hodgkin
5
Rhabdomyosarcoma
4
Neoplasm Metastasis
4
Kidney Neoplasms
4
Gliosarcoma
4
Glioblastoma
4
Breast Neoplasms
4
Brain Neoplasms
4
Waldenstrom Macroglobulinemia
3
Osteosarcoma
3
Melanoma
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Endometrial Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Liposarcoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Glioma
2
Fallopian Tube Neoplasms
2
Carcinoma, Hepatocellular
2
Interventions
Gemcitabine
47
Cisplatin
32
pembrolizumab
28
Paclitaxel
13
Docetaxel
13
avelumab
12
Mitomycin
12
atezolizumab
11
Nivolumab
11
Cystectomy
10
Carboplatin
9
durvalumab
7
Sunitinib
7
apaziquone
6
Doxorubicin
6
BCG Vaccine
6
5-aminolevulinic acid hexyl ester
6
Vinblastine
5
Radiation
5
Platinum
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
Albumin-Bound Paclitaxel
5
Taxes
4
Standard of Care
4
Sorafenib
4
Radiotherapy
4
Fluorouracil
4
Erlotinib Hydrochloride
4
1,2-diaminocyclohexaneplatinum II citrate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Urinary Bladder Neoplasms
×
temsirolimus
×
Clear all
NCT01827943
2021-05-06
VESTOR
Institut Bergonié
Phase 2
Completed
54 enrolled
8 charts